Robert Scott, MD
Cardiovascular Disease · Phoenix, AZNPI 1659354652
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,368 of the $106,191 with a category attached, or 86.0%. Actelion Pharmaceuticals US, Inc. accounts for 89.3% of it on its own, with 8 other manufacturers making up the rest. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 107 payments — averaging $992.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$95K
- Bayer$10K
- Novartis$716
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$183
- United Therapeutics Corporation$146
- Abbott$127
- plus $248 from 3 others
Across 57 payments — averaging $3942.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$141K
- Actelion Pharmaceuticals, Ltd$53K
- Medtronic$20K
- United Therapeutics Corporation$8K
- Actelion Pharmaceuticals US, Inc.$3K
What the payments were for
- Speaking & faculty fees$91,36886%
- Travel & lodging$10,87610%
- Food & beverage$3,9474%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 88 | $94,789 |
| Bayer | 9 | $9,982 |
| Novartis | 1 | $716 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $183 |
| United Therapeutics Corporation | 2 | $146 |
| Abbott | 2 | $127 |
| Edwards Lifesciences | 1 | $126 |
| Novo Nordisk | 1 | $102 |
| Inspire Medical Systems, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$86,376
- OPSUMIT$77,875
- Adempas$9,959
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$126
- TYVASO$125
- CardioMEMS HF System$102
- LifeVest$100
How this compares
$106,191 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 217 | $4,591,518 |
| OpsumitMacitentan | 362 | $4,417,142 |
| AdempasRiociguat | 113 | $1,507,389 |
| WinrevairSotatercept-Csrk | 29 | $516,154 |
| Tyvaso DpiTreprostinil | 19 | $433,133 |
| EntrestoSacubitril/Valsartan | 162 | $191,034 |
| EliquisApixaban | 102 | $132,215 |
| JardianceEmpagliflozin | 74 | $84,930 |
| FarxigaDapagliflozin Propanediol | 70 | $65,009 |
| Ambrisentan | 21 | $45,208 |
| XareltoRivaroxaban | 29 | $33,207 |
| Sirolimus | 36 | $22,542 |
| Tacrolimus | 151 | $17,486 |
| Repatha SureclickEvolocumab | 19 | $14,798 |
| Mycophenolate Mofetil | 68 | $10,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $94,789 | $9,008,660579 claims |
| BayerAdempas | $9,982 | $1,507,389113 claims |
| NovartisEntresto | $716 | $191,034162 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Tabitha MoePhoenix$182K
- Jesse SethiPhoenix$150K
- Kethes WaramPhoenix$66K
- Ayman JamalPhoenix$42K
- Sarika DesaiPhoenix$41K
- Suzanne SorofPhoenix$29K
- Namit RohantPhoenix$25K
- Venkataramanan GangadharanPhoenix$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.